2024 Q3 Form 10-Q Financial Statement

#000117887924000009 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $141.5M $126.7M
YoY Change 36.73% 34.04%
Cost Of Revenue $13.28M $11.26M
YoY Change 33.51% 23.56%
Gross Profit $128.2M $115.4M
YoY Change 37.07% 35.16%
Gross Profit Margin 90.62% 91.11%
Selling, General & Admin $75.11M $73.58M
YoY Change 14.4% 12.46%
% of Gross Profit 58.57% 63.75%
Research & Development $26.16M $24.68M
YoY Change -35.73% -29.78%
% of Gross Profit 20.4% 21.39%
Depreciation & Amortization $2.170M $2.182M
YoY Change -2.6% -1.09%
% of Gross Profit 1.69% 1.89%
Operating Expenses $106.6M $100.4M
YoY Change -3.62% -3.65%
Operating Profit $21.66M $14.97M
YoY Change -227.23% -179.36%
Interest Expense -$11.61M -$11.14M
YoY Change -189.41% -189.19%
% of Operating Profit -53.61% -74.44%
Other Income/Expense, Net -$3.263M -$3.717M
YoY Change -185.13% -65.91%
Pretax Income $6.785M $108.0K
YoY Change -127.46% -100.27%
Income Tax $13.51M $15.81M
% Of Pretax Income 199.17% 14634.26%
Net Earnings -$6.729M -$15.70M
YoY Change -68.81% -63.69%
Net Earnings / Revenue -4.75% -12.39%
Basic Earnings Per Share -$0.02 -$0.05
Diluted Earnings Per Share -$0.02 -$0.05
COMMON SHARES
Basic Shares Outstanding 296.6M shares 296.2M shares
Diluted Shares Outstanding 304.7M shares 303.8M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $249.8M $260.1M
YoY Change -10.9% -2.09%
Cash & Equivalents $233.6M $209.3M
Short-Term Investments $16.11M $50.73M
Other Short-Term Assets $35.31M $35.15M
YoY Change -33.01% -32.54%
Inventory $115.3M $81.32M
Prepaid Expenses
Receivables $98.07M $85.17M
Other Receivables $0.00 $0.00
Total Short-Term Assets $498.5M $461.7M
YoY Change 7.6% 6.67%
LONG-TERM ASSETS
Property, Plant & Equipment $30.44M $31.16M
YoY Change -2.04% 3.05%
Goodwill $197.8M $197.8M
YoY Change 0.0% 0.0%
Intangibles $18.03M $18.85M
YoY Change -15.44% -14.87%
Long-Term Investments
YoY Change
Other Assets $18.68M $17.36M
YoY Change -11.6% -8.86%
Total Long-Term Assets $288.1M $287.8M
YoY Change -4.24% -3.19%
TOTAL ASSETS
Total Short-Term Assets $498.5M $461.7M
Total Long-Term Assets $288.1M $287.8M
Total Assets $786.6M $749.5M
YoY Change 2.94% 2.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.48M $32.06M
YoY Change -41.78% 137.07%
Accrued Expenses $144.7M $136.0M
YoY Change -1.12% 2.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $158.1M $168.1M
YoY Change -6.68% 5.55%
LONG-TERM LIABILITIES
Long-Term Debt $389.5M $388.9M
YoY Change -1.17% -1.12%
Other Long-Term Liabilities $13.48M $12.95M
YoY Change 50.38% 43.16%
Total Long-Term Liabilities $13.48M $12.95M
YoY Change 50.38% 43.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $158.1M $168.1M
Total Long-Term Liabilities $13.48M $12.95M
Total Liabilities $607.7M $617.0M
YoY Change -3.66% -0.25%
SHAREHOLDERS EQUITY
Retained Earnings -$2.800B -$2.748B
YoY Change 3.7% 5.7%
Common Stock $2.909B $2.872B
YoY Change 4.25% 4.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $178.8M $132.5M
YoY Change
Total Liabilities & Shareholders Equity $786.6M $749.5M
YoY Change 2.94% 2.66%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$6.729M -$15.70M
YoY Change -68.81% -63.69%
Depreciation, Depletion And Amortization $2.170M $2.182M
YoY Change -2.6% -1.09%
Cash From Operating Activities -$22.97M $22.69M
YoY Change -40.1% -240.65%
INVESTING ACTIVITIES
Capital Expenditures $356.0K $1.098M
YoY Change -77.32% -50.14%
Acquisitions
YoY Change
Other Investing Activities $34.63M -$20.88M
YoY Change -7.24% -140.0%
Cash From Investing Activities $34.27M -$21.98M
YoY Change -4.16% -143.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 18.19M -857.0K
YoY Change -51.65% -103.62%
NET CHANGE
Cash From Operating Activities -22.97M 22.69M
Cash From Investing Activities 34.27M -21.98M
Cash From Financing Activities 18.19M -857.0K
Net Change In Cash 29.49M -143.0K
YoY Change -15.81% -100.25%
FREE CASH FLOW
Cash From Operating Activities -$22.97M $22.69M
Capital Expenditures $356.0K $1.098M
Free Cash Flow -$23.33M $21.59M
YoY Change -41.57% -217.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
292071201 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
292071201 shares
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
90000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2700000000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
250077000 usd
CY2024Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
436000 usd
CY2024Q2 fold Amortization Deferred Financing Costs
AmortizationDeferredFinancingCosts
124000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
126669000 usd
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
296428877 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
296428877 shares
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2144000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-15697000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
132523000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
160174000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4317000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-18405000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
47000000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-9000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3562000 usd
us-gaap Net Income Loss
NetIncomeLoss
-64116000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
132523000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
102573000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1750000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-1202000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16577000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
24199000 usd
CY2023Q2 fold Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
12000 usd
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
24000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
10880000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-43232000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
111581000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
123047000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4405000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-14008000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
51471000 usd
fold Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
12000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26553000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-61000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
16326000 usd
us-gaap Net Income Loss
NetIncomeLoss
-96164000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
111581000 usd
us-gaap Profit Loss
ProfitLoss
-64116000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1091000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4336000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
47000000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
fold Foreign Currency Remeasurement Gain Loss Before Tax
ForeignCurrencyRemeasurementGainLossBeforeTax
-9391000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-6520000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
447000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
26901000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-13959000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2641000 usd
fold Increase Decrease In Noncurrent Operating Liabilities
IncreaseDecreaseInNoncurrentOperatingLiabilities
-478000 usd
us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7004000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
62335000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
73866000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2909000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14440000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
78000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
18405000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4317000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
fold Proceeds From The Issuance Of Shares In Connection With At The Market Offering Net Of Issuance Costs
ProceedsFromTheIssuanceOfSharesInConnectionWithAtTheMarketOfferingNetOfIssuanceCosts
0 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14166000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2110000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-37720000 usd
us-gaap Interest Paid Net
InterestPaidNet
23790000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1126000 usd
fold Noncash Leasehold Improvements
NoncashLeaseholdImprovements
120000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accounts receivable at June 30, 2024 have primarily arisen from Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span> sales in Europe, the U.S., and Japan. The Company periodically assesses the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
400000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
126669000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
209300000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
50700000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
209335000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
209335000 usd
CY2024Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities
CashCashEquivalentsAndAvailableforsaleDebtSecurities
260061000 usd
CY2024Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000 usd
CY2024Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000 usd
CY2024Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
260062000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
209335000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
209335000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
50726000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
50727000 usd
CY2024Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities
CashCashEquivalentsAndAvailableforsaleDebtSecurities
260061000 usd
CY2024Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000 usd
CY2024Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000 usd
CY2024Q2 fold Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
260062000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
246994000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
246994000 usd
CY2023Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities
CashCashEquivalentsAndAvailableforsaleDebtSecurities
286190000 usd
CY2023Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000 usd
CY2023Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000 usd
CY2023Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
286200000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
246994000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
246994000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
39196000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
39206000 usd
CY2023Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities
CashCashEquivalentsAndAvailableforsaleDebtSecurities
286190000 usd
CY2023Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000 usd
CY2023Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000 usd
CY2023Q4 fold Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure
CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
286200000 usd
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
45700000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
209335000 usd
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3022000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
212357000 usd
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
44909000 usd
CY2024Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
29397000 usd
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7014000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
81320000 usd
CY2024Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3100000 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
388939000 usd
CY2024Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
11941000 usd
CY2024Q1 fold Restructuring And Related Activities Number Of Leases Abandoned
RestructuringAndRelatedActivitiesNumberOfLeasesAbandoned
1 lease
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
23002000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.69
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4521000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.79
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
576000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
305000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
106000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
15.44
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26536000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.11
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M18D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8600000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
24787000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.07
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
8500000 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
16639000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.67
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y10M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
8300000 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16197000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16577000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47000000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51471000 usd
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
58017000 usd
CY2024Q2 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
7341000 usd
CY2024Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
7341000 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
46686000 usd
CY2023Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
7531000 usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
7531000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-15697000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-43232000 usd
us-gaap Net Income Loss
NetIncomeLoss
-64116000 usd
us-gaap Net Income Loss
NetIncomeLoss
-96164000 usd
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
303773922 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
303773922 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
292797002 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
292797002 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36081000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33773000 shares
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001178879-24-000009-index-headers.html Edgar Link pending
0001178879-24-000009-index.html Edgar Link pending
0001178879-24-000009.txt Edgar Link pending
0001178879-24-000009-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
firstamendmenttoamicuswuxi.htm Edgar Link pending
fold-06302024xex311.htm Edgar Link pending
fold-06302024xex312.htm Edgar Link pending
fold-06302024xex321.htm Edgar Link pending
fold-20240630.htm Edgar Link pending
fold-20240630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
fold-20240630_cal.xml Edgar Link unprocessable
fold-20240630_def.xml Edgar Link unprocessable
fold-20240630_lab.xml Edgar Link unprocessable
fold-20240630_pre.xml Edgar Link unprocessable
fold-20240630_htm.xml Edgar Link completed
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable